Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) EBITDA Margin: 2019-2025

Historic EBITDA Margin for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -285.39%.

  • C4 Therapeutics' EBITDA Margin fell 13065.00% to -285.39% in Q3 2025 from the same period last year, while for Sep 2025 it was -396.74%, marking a year-over-year decrease of 8743.00%. This contributed to the annual value of -295.46% for FY2024, which is 32356.00% up from last year.
  • Latest data reveals that C4 Therapeutics reported EBITDA Margin of -285.39% as of Q3 2025, which was up 29.31% from -403.73% recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' EBITDA Margin peaked at -81.07% during Q4 2021, and registered a low of -1,322.30% during Q2 2023.
  • For the 3-year period, C4 Therapeutics' EBITDA Margin averaged around -586.76%, with its median value being -403.73% (2025).
  • In the last 5 years, C4 Therapeutics' EBITDA Margin tumbled by 117,727bps in 2022 and then soared by 117,424bps in 2024.
  • Quarterly analysis of 5 years shows C4 Therapeutics' EBITDA Margin stood at -81.07% in 2021, then crashed by 117,727bps to -1,258.34% in 2022, then soared by 21,642bps to -1,041.92% in 2023, then surged by 36,634bps to -675.58% in 2024, then plummeted by 13,065bps to -285.39% in 2025.
  • Its EBITDA Margin stands at -285.39% for Q3 2025, versus -403.73% for Q2 2025 and -363.80% for Q1 2025.